Optimization design and drug analysis of cardiomyocytebased biosensor
WANG Qin, FANG Jia ru, CAO Duan xi, ZHOU Jie, SU Kai qi, LI Hong bo, WANG Ping
Biosensor National Special Laboratory, Key Laboratory of Biomedical Engineering of Ministry of Education,
College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou 310027, China
The coupling property between cardiomyocytes and microelectrode array (MEA) was studied from two aspects, including MEA surface hydrophilicity and cell culture density, in order to build a cardiomyocytebased potential biosensor of high stability and high consistency. MEA surface hydrophilicity was improved by high molecular protein (gelatin) modification, and the characteristics of extracellular field potential (EFP) signals of cardiomyocytebased potential biosensor under different cell densities were emphatically analyzed. Results show that the highclosely coupling between cardiomyocytes and MEA is formed after cardiomyocytes seeded on the MEA with gelatin modification at the proper cell density of 1.2×105 cells/cm2. Under the optimal conditions, the cardiomyocytebased potential biosensor presents highstable and highconsistent EFP signals, the spike amplitude (SA) reaches about 1.2 mV, and the firing rate (FR) reaches about 180 beats/min, which continues for 34 days. Two typical tool drugs, isoprotenol (ISO) and lidocaine (LID) were applied to test the analytical performance of the optimized cardiomyocytebased potential biosensor. Results show that SA and FR markedly increase after the treatment of 20 μM ISO for 5 min and significantly decrease after the treatment of 20 μM LID for 5 min. This biosensor performed rapid and sensitive response to these two drugs and will provide a promising platform for drug detection and analysis.
WANG Qin, FANG Jia ru, CAO Duan xi, ZHOU Jie, SU Kai qi, LI Hong bo, WANG Ping. Optimization design and drug analysis of cardiomyocytebased biosensor. JOURNAL OF ZHEJIANG UNIVERSITY (ENGINEERING SCIENCE), 2016, 50(6): 1214-1220.
［1］ REDFERN W, CARLSSON L, DAVIS A. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development ［J］. Cardiovascular Research, 2003, 58(1): 32-45.
［2］ LAVERTY H, BENSON C, CARTWRIGHT E, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines ［J］. British Journal of Pharmacology, 2011, 163(4): 675-693.
［3］ BOWES J, BROWN A J, HAMON J, et al. Reducing safetyrelated drug attrition: the use of in vitro pharmacological profiling ［J］. Nature Reviews Drug Discovery, 2012, 11(12): 909-922.
［4］ LEXCHIN J. Drug withdrawals from the Canadian market for safety reasons, 19632004 ［J］. Canadian Medical Association Journal, 2005, 172(6): 765-767.
［5］ MOSS A J, KASS R S. Long QT syndrome: from channels to cardiac arrhythmias ［J］. Journal of Clinical Investigation, 2005, 115(8): 2018-2024.
［6］ BRAAM S. R, TERTOOLEN L, VAN DE STOLPE A, et al. Prediction of druginduced cardiotoxicity using human embryonic stem cellderived cardiomyocytes ［J］. Stem Cell Research, 2010, 4(2): 107-116.
［7］ GIORGI M A, BOLANOS R, GONZALEZ C D, et al. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications ［J］. Current Drug Safety, 2010, 5(1): 54-57.
［8］ NATARAJAN A, STANCESCU M, DHIR V, et al. Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform ［J］. Biomaterials, 2011, 32(18): 4267-4274.
［9］ HANCOX J C, MCPATE M J, EL HARCHI A. The hERG potassium channel and hERG screening for druginduced torsades de pointes ［J］. Pharmacology and Therapeutics, 2008, 119(2): 118-132.
［10］ HANSEN A, EDER A, BNSTRUP M, et al. Development of a drug screening platform based on engineered heart tissue ［J］. Circulation Research, 2010, 107(1): 35-44.
［11］ CHI K R. Revolution dawning in cardiotoxicity testing ［J］. Nature Reviews Drug Discovery, 2013, 12(8):565-567.
［12］ ABASSI Y A, XI B, LI N, et al. Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment ［J］. British Journal of Pharmacology, 2012,165(5): 1424-1441.
［13］ MANDENIUS C F, STEEL D, NOOR F, et al. Cardiotoxicity testing using pluripotent stem cellderived human cardiomyocytes and stateoftheart bioanalytics: a review ［J］. Journal of Applied Toxicology, 2011, 31(3): 191-205.
［14］ FERMINI B, FOSSA A A. The impact of druginduced QT interval prolongation on drug discovery and development ［J］. Nature Reviews Drug Discovery, 2003, 2(6): 439-447.
［15］ XIAO L, HU Z, ZHANG W, et al. Evaluation of doxorubicin toxicity on cardiomyocytes using a dual functional extracellular biochip ［J］. Biosensors and Bioelectronics, 2010, 26(4): 1493-1499.
［16］ MEYER T, KRAUSHAAR U, GUENTHER E. Microelectrode Array (MEA) high resolution electrophysiological mapping of cardiac cell, tissue and organ preparations ［C］ ∥ 2009 World Congress on Medical Physics and Biomedical Engineering. Munich: IFMBE, 2009: 112-115.
［17］ XU B, JACQUIR S, LAURENT G, et al. Phase space reconstruction of an experimental model of cardiac field potential in normal and arrhythmic conditions ［C］∥2013 Annual International Conference of the IEEE.Osaka: IEEE, 2013: 3274-3277.
［18］ KORNBLUM A, PILLEKAMP F, MATZKIES M, et al. A new model to perform electrophysiological studies in the early embryonic mouse heart ［J］. Cellular Physiology and Biochemistry, 2013, 32(1): 110.
［19］ JOHNSTONE A F, GROSS G W, WEISS D G, et al. Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century ［J］. Neurotoxicology, 2010, 31(4): 331-350.
［20］ CASPI O, ITZHAKI I, KEHAT I, et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes ［J］. Stem Cells and Development, 2009, 18(1): 161-172.
［21］ 徐莹,余辉,张威,等.基于 MEMS 技术的微电极阵列细胞传感器 ［J］.自然科学进展, 2007, 17(9): 1265-1272.
XU Yin, YU Hui, ZHANG Wei, et al. Microelectrode array cell sensor based on MEMS technology ［J］. Process in Natural Science, 2007, 17(9): 1265-1272.
［22］ KANEKO T, NOMURA F, HATTORI A, et al. Improvement of electrical stimulation protocol for simultaneous measurement of extracellular potential with onchip multielectrode array system ［J］. Japanese Journal of Applied Physics, 2012, 51(6S): 06FK02.
［23］ GUO L, ABRAMS R M, BABIARZ J E, et al. Estimating the risk of druginduced proarrhythmia using human induced pluripotent stem cellderived cardiomyocytes ［J］. Toxicological Sciences, 2011, 123(1): 281-289.
［24］ ZOU Y, YAO A, ZHU W, et al. Isoproterenol activates extracellular signalregulated protein kinases in cardiomyocytes through calcineurin ［J］. Circulation, 2001, 104(1): 102-108.
